Replies to post #4832738 on BB's Stock Haven

[BottomBounce]

$CEMI The FDA has granted emergency use authorization to Chembio Diagnostics Inc's
CEMI partner LumiraDx's COVID-19 antibody test.
LumiraDx and Chembio had announced a partnership on March 12, 2020 to develop point of care COVID-19 antibody test.
The nod comes for LumiraDx SARS-CoV-2 Ab Test, a microfluidic immunofluorescence assay for the qualitative detection of total antibodies in whole human blood, plasma, or serum for indication of recent or prior infection.
Recently, the $CEMI received a $28 million order to supply DPP SARS-CoV-2 Antigen tests for delivery during 2021 in Brazil.